Get the Stockscreener App
10.01
1.01%
0.10
After Hours:
10.07
0.06
+0.60%
Capricor Therapeutics Inc stock is traded at $10.01, with a volume of 6.27M.
It is up +1.01% in the last 24 hours and up +160.00% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$9.91
Open:
$10.77
24h Volume:
6.27M
Relative Volume:
1.38
Market Cap:
$581.97M
Revenue:
$11.13M
Net Income/Loss:
$-114.59M
P/E Ratio:
-4.3277
EPS:
-2.313
Net Cash Flow:
$-113.96M
1W Performance:
+20.75%
1M Performance:
+160.00%
6M Performance:
-64.16%
1Y Performance:
+59.39%
1-Day Range:
$9.85
$11.00
1-Week Range:
$8.05
$11.00
52-Week Range:
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
10.01 | 397.38M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
547.65 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
823.82 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.51 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.27 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.87 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Healthcare Strategy Focus - Kalkine Media
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Activist Investor Sounds Alarm on Capricor’s Cash Burn - TradingView
/C O R R E C T I O N — Kessler Topaz Meltzer & Check, LLP/ - Morningstar
Activist Investor Kaos Capital Demands Board Overhaul at Capricor Ahead of FDA Decision on DMD Therapy - finance.biggo.com
INVESTOR DEADLINE: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit Before September 28, 2026 Deadline - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - lincolnjournal.com
Capricor Stock Faces Securities-Fraud Case as FDA Review Stays Open - TechStock²
Kaos Capital Pushes for Strategic Board Meeting at Capricor Ther - GuruFocus
Kaos Capital pushes for board changes at Capricor Therapeutics - Investing.com
Kaos Capital pushes for board changes at Capricor Therapeutics By Investing.com - Investing.com Canada
Capricor shareholder cites ~$80.2M cash drop and seeks spending cuts - Stock Titan
Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders - Yahoo Finance
Duchenne Cell Therapy Shifts Its Target from the Heart to Arm Function as Decision Date Slips - Medical Daily
Shareholder pressures Capricor; Lilly dives deeper into vaccines - Yahoo Finance
Capricor (CAPR) Q2 2026 Earnings Call Transcript - AOL.com
Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy - Stocktwits
Capricor (CAPR) Q2 2026 Earnings Call Transcript - The Motley Fool
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm to Learn About Their Legal Rights - The Globe and Mail
Deadline Alert: Capricor Therapeutics, Inc. (CAPR) - GlobeNewswire
Capricor Therapeutics (CAPR) Faces Valuation Challenges Ahead of FDA Decision - GuruFocus
Capricor Therapeutics, Inc. Investors Have Opportunity to - GlobeNewswire
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities LawsuitContact SueWallSt - Morningstar
Capricor Therapeutics (CAPR) Faces Market Pressure Amid FDA Conc - GuruFocus
Capricor Therapeutics Shareholder Alert: ClaimsFiler - GlobeNewswire
Capricor slips on potential Deramiocel rejection (CAPR:NASDAQ) - Seeking Alpha
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesCAPR - PR Newswire
Piper Sandler Downgrades Capricor Therapeutics, Cuts Target to $2 - scanx.trade
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT - GlobeNewswire
$Capricor Therapeutics (CAPR.US)$ FDA APPROVAL 2026-08-22 in two days get ready!!! - Moomoo
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (N - The National Law Review
Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track? - Yahoo Finance
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026 - Barchart.com
Capricor Therapeutics (CAPR): Millennium stake slips under 5% - Stock Titan
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor - GlobeNewswire
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - TMX Newsfile
CAPR EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026 - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Capricor - GlobeNewswire
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit: Investors Face September 28, 2026, Deadline - NewMediaWire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
CAPR Investor Reminder: Capricor Therapeutics Securities - GlobeNewswire
Capricor Therapeutics, Inc. Notice of September 28, 2026 - GlobeNewswire
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc. - WBOC TV
CAPR INVESTOR REMINDER: Capricor Therapeutics, Inc. Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role - lincolnjournal.com
Kaplan Fox & Kilsheimer LLP Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before September 28, 2026 - Barchart.com
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6% - Stocktwits
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
11,223 |
0.33%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):